Septerna (NASDAQ:SEPN) Shares Up 8.4% – What’s Next?

Septerna, Inc. (NASDAQ:SEPN) traded up 8.4% on Monday . The company traded as high as $26.43 and last traded at $26.31. 52,213 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 337,603 shares. The stock had previously closed at $24.28.

Analysts Set New Price Targets

A number of research firms recently issued reports on SEPN. Wells Fargo & Company started coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective for the company. TD Cowen started coverage on Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating for the company. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price objective on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 target price for the company.

Septerna Price Performance

Insiders Place Their Bets

In other news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $6,669,000.00. Following the acquisition, the insider now directly owns 6,215,591 shares of the company’s stock, valued at $111,880,638. The trade was a 6.34 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.